A randomized, open-label, 2-period, crossover bioequivalence study of two oral formulations of 75 mg oseltamivir in healthy Thai volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 46, Issue 12, 2008, Pages 654-662

  Kongpatanakul, S ^a   Chatsiricharoenkul, S ^a   Panich, U ^a   Sathirakul, K ^b   Pongnarin, P ^a   Sangvanich, P ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Active metabolite; Bioequivalence; Neuraminidase inhibitor; Oral formulation; Oseltamivir Pharmacokinetics

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; GENERIC DRUG; GOP A FLU; OSELTAMIVIR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD EXAMINATION; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DERMATITIS; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DETERMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SYNCOPE; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN; VOMITING;

EID: 57149141024     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP46654     Document Type: Article

References (25)

1. Bardsley-Elliot A, Noble S. Oseltamivir. Drugs. 1999; 58: 851-860.
2. Brewster M, Smith JR, Dutkowski R, Robson R. Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, open-label study. Vaccine. 2006; 24: 6660-6663.
3. Chen ML, Shah V Patnaik R, Adams W Hussain A, Conner D, Mehra M, Malinowski H, Lazor J, Huang SM, Hare D, Lesko L, Sporn D, Williams R. Bioavailability and bioequivalence: an FDA regulatory overview. Pharm Res. 2001; 18: 1645-1650.
4. Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY Nicholson KG, Bohnen AM, Hirst HM, Keene O, Wightman K. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med. 1997; 337: 874-880.
5. Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, Kinnersley N, Mills RG, Ward P, Straus SE. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA. 1999; 282: 1240-1246.
6. Hayden FG, Pavia AT. Antiviral management of seasonal and pandemic influenza. J Infect Dis. 2006; 194: 119-126.
7. Hill G, Ohlar T, Oo C, Ho ES, Prior K, Wiltshire H, Barrett J, Liu B, Ward P. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos. 2002; 30: 13-19.
8. Jackson AJ, Robbie G, Marrown P. Metabolites and bio-equivalence: past and present, Clin Pharmacokinet. 2004; 43: 655-672.
9. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A. Antivirals for influenza in healthy adults: systematic review. Lancet. 2006; 367: 303-313.
10. Kawai N, Ikematsu H, Iwaki N, Satoh I, Kawashima T, Maeda T, Miyachi K, Hirotsu N, Shigematsu T, Kashiwagi S. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season. Clin Infect Dis. 2005; 40: 1309-1316.
11. Lindegardh N, Davies GR, Tran TH, Farrar J, Singhasivanon P, Day NP, White NJ. Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases. Antimicrob Agents Chemother. 2006; 50: 3197-3199.
12. Marsh S, Xiao M, Yu J, Ahluwalia R, Minton M, Freimuth RR, Kwok PY, McLeod HL. Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics. 2004; 84: 661-668.
13. McClellan K, Perry CM. Oseltamivir: a review of its use in influenza. Drugs. 2001; 61: 263-283.
14. Meredith P. Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther. 2003; 25: 2875-2890.
15. Midha KK, Rawson MJ, Hubbard JW. The role of metabolites in bioequivalence. Pharm Res. 2004; 21: 1331-1344.
16. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005; 353: 1363-1373.
17. Oo C, Snell, P Barrett J, Darr A, Liu B, Wilding I. Pharmacokinetics and delivery of the anti-influenza pro-drug oseltamivir to the small intestine and colon using site-specific delivery capsules. Int J Pharm. 2003; 257: 297-299.
18. Rothberg MB, Bellantonio S, Rose DN. Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy. Ann Intern Med. 2003; 139: 321-329.
19. Schentag JJ, Hill G, Chu T, Rayner CR. Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects. J Clin Pharmacol. 2007; 47: 689-696.
20. Snell P, Dave N, Wilson K, Rowell L, Weil A, Galitz L, Robson R. Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate. Br J Clin Pharmacol. 2005; 59: 598-601.
21. Snell P, Oo C, Dorr A, Barrett J. Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids. Br J Clin Pharmacol. 2002; 54: 372-377.
22. Sweeny DJ, Lynch G, Bidgood AM, Lew W, Wang KY, Cundy KC. Metabolism of the influenza neuraminidase inhibitor prodrug oseltamivir in the rat. Drug Metab Dispos. 2000; 28: 737-741.
23. Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess. 2003; 7: 1-170.
24. Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother. 2005; 55: 5-21.
25. US Food and Drug Administration. Guidance for Industry, Bioanalytical Method Validation. FDA Rockville, MD, 2001. US Food and Drug Administration. Guidance for industry, bioavailability and bioequivalence studies for orally administered drug products - general considerations. Rockville: MD, FDA; 2003.